ERC Starting Grant · 2024
Exploiting the activity of the ALDH enzyme to develop highly selective drugs for cancer stem cells
Despite huge advances in cancer treatment, resistance to chemotherapy is still common. It is now well established that a small population of cells named cancer stem cells (CSCs) have high tumorigenicity and are able to initiate and maintain a tumour. CSCs usually remain in a quiescent state that is not affected by standard chemotherapy; thus, they are often responsible for treatment resistance and relapse. There is a clear need to find effective treatments against CSCs to fully eradicate the tumour. However, the close similarities of CSCs to healthy stem cells hinders the identification of selective drugs. In the last years, new drug modalities are emerging to provide therapeutic options…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.